CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors Life Science Investing
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update Life Science Investing
CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-1-Positive First-Line Metastatic Triple-Negative Breast Cancer Life Science Investing
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Pharmaceutical Investing
FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer Pharmaceutical Investing
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA Robotic Surgical System Pharmaceutical Investing
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 Life Science Investing
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure Life Science Investing
